Emerging Targets to Relieve Fat Stress-Induced Liver Diseases: UDCA, Tocotrienol, omega-3 PUFAs, and IgY Targeted NPC1L1 Cholesterol Transporter
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Cha, Ji-Young | - |
dc.contributor.author | Park, Jong-Min | - |
dc.contributor.author | Lee, Ho-Jae | - |
dc.contributor.author | Bae, Jin-Sik | - |
dc.contributor.author | Han, Young-Min | - |
dc.contributor.author | Oh, Byung-Chul | - |
dc.contributor.author | Ko, Kwang Hyun | - |
dc.contributor.author | Hahm, Ki-Baik | - |
dc.date.available | 2020-02-27T23:42:36Z | - |
dc.date.created | 2020-02-07 | - |
dc.date.issued | 2017-07 | - |
dc.identifier.issn | 1381-6128 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/7548 | - |
dc.description.abstract | Fat stress-induced liver disease is a hepatic manifestation of metabolic syndrome initiated by excess fat accumulation and encompasses a wide spectrum of diseases from non-alcoholic fatty liver disease to nonalcoholic steatohepatitis, a precursor lesion progressing to more aggressive liver cirrhosis and hepatocellular carcinoma. Although the incidence of these fat stress-induced liver diseases is rapidly increasing worldwide in parallel with the growing epidemics of obesity and metabolic diseases, its exact pathogenesis is not well defined. Although obesity, sedentary life-style, altered dietary pattern, insulin resistance, altered intestinal barrier function, inflammatory cytokines, and oxidative stress have been acknowledged as contributing factors because of the indefinite pathogenesis of metabolic diseases, the only reliable treatment is lifestyle intervention composed of restrictive diet and exercise. Additionally, some existing medications such as pioglitazone and antioxidants such as vitamin E were reported to be effective; in this review, several novel agents especifically targeting nonalcoholic fatty liver disease pathogenesis under clinical trial will be introduced. These include an NPC1L1 blocker (ezetimibe), which significantly improved histological and symptomatic scores associated with steatohepatitis and fibrosis; clofibrate, phentoxyfylline, ursodeoxycholic acid, and tocopherol, all of which are prescribed to relieve fat stress; and additional IgY targeted NPC1L1, tocotrienol, ursodeoxycholic acid, and omega-3 polyunsaturated fatty acids, which are actively under investigation to confirm the safety of long- term use. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | BENTHAM SCIENCE PUBL LTD | - |
dc.relation.isPartOf | CURRENT PHARMACEUTICAL DESIGN | - |
dc.title | Emerging Targets to Relieve Fat Stress-Induced Liver Diseases: UDCA, Tocotrienol, omega-3 PUFAs, and IgY Targeted NPC1L1 Cholesterol Transporter | - |
dc.type | Article | - |
dc.type.rims | ART | - |
dc.description.journalClass | 1 | - |
dc.identifier.wosid | 000414143700005 | - |
dc.identifier.doi | 10.2174/1381612823666170714124824 | - |
dc.identifier.bibliographicCitation | CURRENT PHARMACEUTICAL DESIGN, v.23, no.27, pp.3941 - 3951 | - |
dc.description.isOpenAccess | N | - |
dc.identifier.scopusid | 2-s2.0-85038624521 | - |
dc.citation.endPage | 3951 | - |
dc.citation.startPage | 3941 | - |
dc.citation.title | CURRENT PHARMACEUTICAL DESIGN | - |
dc.citation.volume | 23 | - |
dc.citation.number | 27 | - |
dc.contributor.affiliatedAuthor | Cha, Ji-Young | - |
dc.contributor.affiliatedAuthor | Lee, Ho-Jae | - |
dc.contributor.affiliatedAuthor | Bae, Jin-Sik | - |
dc.contributor.affiliatedAuthor | Oh, Byung-Chul | - |
dc.type.docType | Review | - |
dc.subject.keywordAuthor | Non-alcoholic fatty liver disease | - |
dc.subject.keywordAuthor | non-alcoholic steatohepatitis | - |
dc.subject.keywordAuthor | liver fibrosis | - |
dc.subject.keywordAuthor | pharmacological therapy | - |
dc.subject.keywordAuthor | tocotrienol | - |
dc.subject.keywordAuthor | ursodeoxycholic acid | - |
dc.subject.keywordAuthor | IgY targeted NPC1L1 | - |
dc.subject.keywordAuthor | fatty acids | - |
dc.subject.keywordPlus | HELICOBACTER-PYLORI INFECTION | - |
dc.subject.keywordPlus | UREASE IMMUNOGLOBULIN-Y | - |
dc.subject.keywordPlus | EGG-YOLK ANTIBODIES | - |
dc.subject.keywordPlus | NF-KAPPA-B | - |
dc.subject.keywordPlus | VITAMIN-E | - |
dc.subject.keywordPlus | URSODEOXYCHOLIC ACID | - |
dc.subject.keywordPlus | GAMMA-TOCOTRIENOL | - |
dc.subject.keywordPlus | NONALCOHOLIC STEATOHEPATITIS | - |
dc.subject.keywordPlus | MITOCHONDRIAL DYSFUNCTION | - |
dc.subject.keywordPlus | HEPATOCELLULAR-CARCINOMA | - |
dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
dc.relation.journalWebOfScienceCategory | Pharmacology & Pharmacy | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
1342, Seongnam-daero, Sujeong-gu, Seongnam-si, Gyeonggi-do, Republic of Korea(13120)031-750-5114
COPYRIGHT 2020 Gachon University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.